• Wed, Jan. 11, 7:11 AM
    • Globus Medical (NYSE:GMED) announces preliminary unaudited sales results for the Q4 and full year ending December 31, 2016.
    • The company anticipates Q4 and full year sales of ~$151.6M and ~$564M respectively.
    • The company established FY2017 guidance of $625M in sales and EPS of $1.27.
    • The company expects to announce its earnings release in late February.
    Wed, Jan. 11, 7:11 AM
  • Dec. 5, 2016, 9:16 AM
    Dec. 5, 2016, 9:16 AM
  • Nov. 11, 2016, 6:52 AM
    • Valeant Pharmaceuticals (NYSE:VRX) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $23 (37% upside) from $81.
    • WellCare Health Plans (NYSE:WCG) downgraded to Neutral from Overweight by JPMorgan.
    • Universal Health Services (NYSE:UHS) downgraded to Neutral from Buy by Bank of America. Price target lowered to $135 (12% upside) from $150.
    • UnitedHealth Group (NYSE:UNH) downgraded to Neutral from Buy by Mizuho Securities.
    • Globus Medical (NYSE:GMED) downgraded to Market Perform from Outperform by JMP Securities and William Blair. Downgraded to Market Perform from Outperform by Oppenheimer. Price target lowered to $23 (7% upside) from $29. Downgraded to Market Perform by Citigroup. Price target lowered to $23 (7% upside) from $29.
    • Kindred Healthcare (NYSE:KND) downgraded to Sell from Hold by Stifel Nicolaus. Price target lowered to $5 (19% downside risk) from $10. Downgraded to Sector Perform by RBC Capital Markets and Royal Bank of Canada. Price target lowered to $9 (46% upside) from $16 by both.
    • Impax Laboratories (NASDAQ:IPXL) downgraded to Underperform from Neutral with a $19 (32% upside) price target by Bank of America.
    • BioMarin Pharmaceutical (NASDAQ:BMRN) downgraded to Neutral from Overweight by Piper Jaffray. Price target lowered to $84 (10% downside risk) from $105.
    Nov. 11, 2016, 6:52 AM | 26 Comments
  • Nov. 8, 2016, 5:40 PM
    Nov. 8, 2016, 5:40 PM
  • Nov. 8, 2016, 4:43 PM
    • Globus Medical (NYSE:GMED): Q3 EPS of $0.29 in-line.
    • Revenue of $135.7M (-0.9% Y/Y) misses by $3.55M.
    • Shares -9.5%.
    • Press Release
    Nov. 8, 2016, 4:43 PM
  • Nov. 7, 2016, 5:35 PM
  • Jul. 27, 2016, 12:44 PM
    Jul. 27, 2016, 12:44 PM
  • Jul. 27, 2016, 11:00 AM
    Jul. 27, 2016, 11:00 AM | 3 Comments
  • Jul. 27, 2016, 9:23 AM
    Jul. 27, 2016, 9:23 AM
  • Jul. 26, 2016, 4:42 PM
    • Globus Medical (NYSE:GMED): Q2 EPS of $0.29 in-line.
    • Revenue of $137.5M (+2.9% Y/Y) misses by $4.28M.
    Jul. 26, 2016, 4:42 PM
  • Jul. 25, 2016, 5:35 PM
  • May 27, 2016, 4:56 PM
    • Globus Medical (NYSE:GMED) initiated with Equal Weight Rating and $26 (8% upside) price target by Barclays.
    • TG Therapeutics (NASDAQ:TGTX) initiated with Buy rating $18 (133% upside) price target by SunTrust Robinson Humphrey.
    • Karyopharm Therapeutics (NASDAQ:KPTI) initiated with Outperform rating and $13 (35% upside) price target by Raymond James.
    • SAGE Therapeutics (NASDAQ:SAGE) initiated with Sell rating and $18 (43% downside risk) price target by Chardan Capital.
    • Viking Therapeutics (NASDAQ:VKTX) initiated with Buy rating with a $5 (285% upside) price target by Maxim Group.
    • Fibrocell Science (NASDAQ:FCSC) resumed with Buy rating and $7 (229% upside) price target by Roth Capital Partners.
    • Asterias Biotherapeutics (NYSEMKT:AST) initiated with Buy rating and $5.50 (61% upside) price target by Chardan Capital.
    • Quorum Health (NYSE:QHC) initiated with Market Perform rating and $14 (6% upside) price target by Avondale Partners.
    • Radius Health (NASDAQ:RDUS) initiated with Buy rating and $55 (57% upside) price target by H.C. Wainwright.
    • Johnson & Johnson (NYSE:JNJ) initiated with Sell rating and $94 (17% downside risk) price target by Standpoint Research.
    • NuVasive (NASDAQ:NUVA) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $63 (15% upside) from $58.
    • Zimmer Biomet Holdings (NYSE:ZBH) upgraded to Buy from Hold with a $125 (2% upside) price target by Argus Research.
    • Relypsa (NASDAQ:RLYP) upgraded to Equal Weight from Underweight with a $9 (50% downside risk) price target by Morgan Stanley. To be adjusted after ZS-9 rejection.
    • Ionis Pharmaceuticals (NASDAQ:IONS) downgraded to Market Perform from Outperform by BMO Capital Markets. Price target lowered to $26 (18% upside) from $55.
    • Patterson Companies (NASDAQ:PDCO) downgraded to Hold from Buy by Evercore ISI. Price target lowered to $48.50 (0% upside) from $49.50.
    • United Therapeutics (NASDAQ:UTHR) downgraded to Sell from Hold with a $114 (3% downside risk) price target by Argus Research.
    • Boston Scientific (NYSE:BSX) downgraded to Neutral from Buy with a $24.20 (7% upside) price target by BTIG Research.
    • Neovasc (NASDAQ:NVCN) downgraded to Neutral from Buy by Ladenburg Thalmann. Price target removed.
    May 27, 2016, 4:56 PM | 17 Comments
  • May 20, 2016, 7:32 AM
    • Arrowhead Pharmaceuticals (NASDAQ:ARWR) initiated with Buy rating and $12 (140% upside) price target by Chardan Capital.
    • Amicus Therapeutics (NASDAQ:FOLD) initiated with Buy rating and $10 (45% upside) price target by Bank of America.
    • Quorum Health (NYSE:QHC) initiated with Equal Weight rating and $12 (2% upside) price target by Morgan Stanley.
    • TESARO (NASDAQ:TSRO) initiated with Outperform rating and $56 (30% upside) price target by Credit Suisse.
    • Prothena (NASDAQ:PRTA) initiated with Overweight rating and $60 (47% upside) price target by Barclays.
    • Mazor Robotics (NASDAQ:MZOR) upgraded to Outperform from Market Perform by Wells Fargo. Price target raised to $15-17 (14% upside from midpoint) from $10-13.
    • Eli Lilly (NYSE:LLY) upgraded to Strong Buy with a price target of $88.67 (19% upside) by the Vetr Community.
    • Haemonetics (NYSE:HAE) upgraded to Neutral from Sell by Goldman Sachs. Price target raised to $29 (5% upside) from $25.
    • Nanosphere (NASDAQ:NSPH) downgraded to Neutral from Buy by Rodman & Renshaw. Price target lowered to $1.35 (2% upside) from $2.00.
    • Anacor Pharmaceuticals (NASDAQ:ANAC) downgraded to Neutral from Buy by Mizuho Securities. Price target set at $99.25 (0% upside).
    • Globus Medical (NYSE:GMED) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to $21 (10% downside risk) from $26.
    • EPIRUS Biopharmaceuticals (NASDAQ:EPRS) downgraded to Market Perform from Outperform by Leerink Swann. Price target lowered to $0.75 (27% upside).
    May 20, 2016, 7:32 AM | 10 Comments
  • May 3, 2016, 4:45 PM
    • Globus Medical (NYSE:GMED): Q1 EPS of $0.29 beats by $0.01.
    • Revenue of $139.3M (+5.9% Y/Y) misses by $1M.
    • Shares +0.7%.
    May 3, 2016, 4:45 PM
  • May 2, 2016, 5:35 PM
  • Feb. 24, 2016, 4:54 PM
    • Globus Medical (NYSE:GMED): Q4 EPS of $0.32 beats by $0.02.
    • Revenue of $142.59M (+10.7% Y/Y) beats by $1.39M.
    Feb. 24, 2016, 4:54 PM